Clinical research
Femtech represents significant growth opportunities for biotech companies, but is still under the radar for most investors. None-the-less, pioneering companies are emerging to address this sector’s many underserved needs.
Gossamer Bio announced today that its two studies examining GB001 – the Phase IIb LEDA trial in eosinophilic asthma and Phase II TITAN trial in chronic rhinosinusitis – failed to meet their primary endpoints.
In a Phase III study, the biologic (Dupixent) met primary and all key secondary endpoints in children ages 6 to 11 who have uncontrolled moderate-to-severe asthma.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
J&J did not disclose much information about the unexplained illness, stating, “We must respect this participant’s privacy. We’re also learning more about this participant’s illness, and it’s important to have all the facts before we share additional information.”
It was a moderately busy week for clinical trial news. Here’s a look.
This morning, the pharma giant announced the PENELOPE-B study failed to hit the mark of improved invasive disease-free survival (iDFS).
The U.S. National Institutes of Health (NIH) is launching a clinical trial of a combination of Gilead Sciences’ antiviral drug remdesivir (Vitrakvy) and hyperimmune intravenous immunoglobulin (hIVIG).
The heart drug met primary endpoint but failed to make the ultimate impact needed.
Results from multiple Phase III trials show consistent improvements in pain relief and physical function.
PRESS RELEASES